Ponatinib in patients with refractory acute myeloid leukaemia: Findings from a phase 1 study

British Journal of Haematology

Volumn 162, Issue 4, 2013, Pages 548-552

  Shah, Neil P ^a   Talpaz, Moshe ^b   Deininger, Michael W N ^c   Mauro, Michael J ^c   Flinn, Ian W ^d   Bixby, Dale ^b   Lustgarten, Stephanie ^e   Gozgit, Joseph M ^e   Clackson, Tim ^e   Turner, Christopher D ^e   Haluska, Frank G ^e   Kantarjian, Hagop ^f   Cortes, Jorge E ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d SARAH CANNON RESEARCH INSTITUTE   (United States)

^e ARIAD PHARMACEUTICALS INC   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myeloid leukaemia; FLT3 internal tandem duplications; FMS like tyrosine kinase 3; Ponatinib; Tyrosine kinase inhibitor

Indexed keywords

CD135 ANTIGEN; PONATINIB; QUIZARTINIB; SORAFENIB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE PANCREATITIS; ADULT; AGED; CANCER RESISTANCE; CLINICAL ARTICLE; DEATH; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; HUMAN; LETTER; LEUKEMIA REMISSION; MULTIPLE ORGAN FAILURE; PETECHIA; PHASE 1 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; SEPSIS; TREATMENT DURATION;

ACUTE MYELOID LEUKAEMIA; FLT3 INTERNAL TANDEM DUPLICATIONS; FMS-LIKE TYROSINE KINASE-3; PONATINIB; TYROSINE KINASE INHIBITOR;

ADULT; AGED; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; PYRIDAZINES; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; TANDEM REPEAT SEQUENCES;

EID: 84880703294     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12382     Document Type: Letter

References (10)

1. Borthakur, G., Kantarjian, H., Ravandi, F., Zhang, W., Konopleva, M., Wright, J.J., Faderl, S., Verstovsek, S., Mathews, S., Andreeff, M. & Cortes, J.E. (2011) Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica, 96, 62-68.
2. Cortes, J., Foran, J., Ghirdaladze, D., DeVetten, M.P., Zodelava, M., Holman, P., Levis, M.J., Kantarjian, H.M., Borthakur, G., James, J., Zarringkar, P.P., Gunawardane, R.N., Armstrong, R.C., Padre, N.M., Wierenga, W., Corringham, R. & Trikha, M. (2009) AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first-in-human (FIH) phase 1 AML study. Blood, 114, Abstract 636.
3. Cortes, J.E., Kantarjian, H., Shah, N.P., Bixby, D., Mauro, M.J., Flinn, I.W., O'Hare, T., Haluska, F.G., Druker, B.J., Deininger, M.W. & Talpaz, M. (2012a) Ponatinib in refractory Philadelphia chromosome-positive leukemias. New England Journal of Medicine, 367, 2075-2088.
4. Cortes, J.E., Kim, D.W., Pinilla-Ibarz, J., le Coutre, P.D., Paquette, R., Chuah, C., Nicolini, F.E., Apperley, J.F., Khoury, H.J., Talpaz, M., DiPersio, J.F., DeAngelo, D.J., Abruzzese, E., Rea, D., Baccarani, M., Müller, M.C., Gambacorti-Passerini, C., Wong, S., Lustgarten, S., Rivera, V.M., Clackson, T., Turner, C.D., Haluska, F.G., Guilhot, F., Deininger, M.W., Hochhaus, A., Hughes, T., Goldman, J.M., Shah, N. & Kantarjian, H.M. & the PACE Study Group (2012b) A pivotal phase 2 trial of ponatinib in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 12-month follow-up of the PACE trial. Blood (ASH Annual Meeting Abstracts), 120, Abstract 163.
5. Gozgit, J.M., Wong, M.J., Wardwell, S., Tyner, J.W., Loriaux, M.M., Mohemmad, Q.K., Narasimhan, N.I., Shakespeare, W.C., Wang, F., Druker, B.J., Clackson, T. & Rivera, V.M. (2011) Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Molecular Cancer Therapeutics, 10, 1028-1035.
6. Knapper, S. (2011) The clinical development of FLT3 inhibitors in acute myeloid leukemia. Expert Opinion on Investigational Drugs, 20, 1377-1395.
7. Levis, M. & Small, D. (2003) FLT3: ITDoes matter in leukemia. Leukemia, 17, 1738-1752.
8. O'Hare, T., Shakespeare, W.C., Zhu, X., Eide, C.A., Rivera, V.M., Wang, F., Adrian, L.T., Zhou, T., Huang, W.S., Xu, Q., Metcalf, C.A. Tyner, J.W., Loriaux, M.M., Corbin, A.S., Wardwell, S., Ning, Y., Keats, J.A., Wang, Y., Sundaramoorthi, R., Thomas, M., Zhou, D., Snodgrass, J., Commodore, L., Sawyer, T.K., Dalgarno, D.C., Deininger, M.W., Druker, B.J. & Clackson, T. (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 16, 401-412.
9. Smith, C.C., Wang, Q., Chin, C.S., Salerno, S., Damon, L.E., Levis, M.J., Perl, A.E., Travers, K.J., Wang, S., Hunt, J.P., Zarrinkar, P.P., Schadt, E.E., Kasarskis, A., Kuriyan, J. & Shah, N.P. (2012) Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature, 485, 260-263.
10. Smith, C.C., Lasater, E.A., Zhu, X., Lin, K.C., Stewart, W.K., Damon, L.E., Salerno, S. & Shah, N.P. (2013) Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood, 121, 3165-3171.